Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity 56, 2188–2205 (2023).
Google Scholar
Lang, F., Schrörs, B., Löwer, M., Türeci, Ö. & Sahin, U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat. Rev. Drug Discov. 21, 261–282 (2022).
Google Scholar
Johnson, D. B., Nebhan, C. A., Moslehi, J. J. & Balko, J. M. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat. Rev. Clin. Oncol. 19, 254–267 (2022).
Google Scholar
Fares, C. M., Allen, E. M. V., Drake, C. G., Allison, J. P. & Hu-Lieskovan, S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am. Soc. Clin. Oncol. Educ. Book 39, 147–164 (2019).
Google Scholar
Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326–336 (2019).
Google Scholar
de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41, 374–403 (2023).
Google Scholar
Almagro, J., Messal, H. A., Elosegui-Artola, A., Rheenen, Jvan & Behrens, A. Tissue architecture in tumor initiation and progression. Trends Cancer 8, 494–505 (2022).
Google Scholar
Shi, R., Tang, Y. & Miao, H. Metabolism in tumor microenvironment: implications for cancer immunotherapy. MedComm 1, 47–68 (2020).
Google Scholar
Kartikasari, A. E. R., Huertas, C. S., Mitchell, A. & Plebanski, M. Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis. Front. Oncol. 11, 692142 (2021).
Google Scholar
Liu, Y., Guo, J. & Huang, L. Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. Theranostics 10, 3099–3117 (2020).
Google Scholar
Leko, V. & Rosenberg, S. A. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell 38, 454–472 (2020).
Google Scholar
Monte, U. D. Does the cell number 109 still really fit one gram of tumor tissue? Cell Cycle 8, 505–506 (2009).
Google Scholar
Mallet, M. et al. Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy. Eur. J. Cancer 171, 96–105 (2022).
Google Scholar
Nagarsheth, N. B. et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat. Med. 27, 419–425 (2021).
Google Scholar
Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).
Google Scholar
Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
Google Scholar
Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486–499 (2015).
Google Scholar
Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195–211.e10 (2019).
Google Scholar
Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417–421 (2016).
Google Scholar
Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370, 1328–1334 (2020).
Google Scholar
Morotti, M. et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br. J. Cancer 124, 1759–1776 (2021).
Google Scholar
Baharom, F. et al. Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells. Nat. Immunol. 22, 41–52 (2021).
Google Scholar
D’Alise, A. M. et al. Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection. Sci. Transl. Med. 14, eabo7604 (2022).
Google Scholar
Quezada, S. A. et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637–650 (2010).
Google Scholar
Magen, A. et al. Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat. Med. 29, 1389–1399 (2023).
Google Scholar
Schietinger, A., Philip, M., Liu, R. B., Schreiber, K. & Schreiber, H. Bystander killing of cancer requires the cooperation of CD4+ and CD8+ T cells during the effector phase. J. Exp. Med. 207, 2469–2477 (2010).
Google Scholar
Alspach, E., Lussier, D. M. & Schreiber, R. D. Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Csh Perspect. Biol. 11, a028480 (2019).
Google Scholar
Espinosa-Carrasco, G. et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42, 1202–1216.e8 (2024).
Google Scholar
Schoenberger, S. P., Toes, R. E. M., Voort, E. I. H., van der, Offringa, R. & Melief, C. J. M. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. Nature 393, 480–483 (1998).
Google Scholar
Ossendorp, F., Mengedé, E., Camps, M., Filius, R. & Melief, C. J. M. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187, 693–702 (1998).
Google Scholar
de Graaf, F. J. et al. Neoantigen-specific T-cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer. Mol. Ther. Oncol. 32, 200835 (2024).
Google Scholar
Ninmer, E. K. et al. Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial. Nat. Commun. 15, 2570 (2024).
Google Scholar
Kappler, J. W., Roehm, N. & Marrack, P. T cell tolerance by clonal elimination in the thymus. Cell 49, 273–280 (1987).
Google Scholar
Pearlman, A. H. et al. Targeting public neoantigens for cancer immunotherapy. Nat. Cancer 2, 487–497 (2021).
Google Scholar
Supabphol, S., Li, L., Goedegebuure, S. P. & Gillanders, W. E. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy. Expert. Opin. Investig. Drugs 30, 529–541 (2021).
Google Scholar
Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal. Transduct. Target. Ther. 8, 9 (2023).
Google Scholar
Fotakis, G., Trajanoski, Z. & Rieder, D. Computational cancer neoantigen prediction: current status and recent advances. Immuno-Oncol. Technol. 12, 100052 (2021).
Google Scholar
Boegel, S., Castle, J. C., Kodysh, J., O’Donnell, T. & Rubinsteyn, A. Bioinformatic methods for cancer neoantigen prediction. Prog. Mol. Biol. Transl. Sci. 164, 25–60 (2019).
Google Scholar
Thrift, W. J. et al. HLApollo: a superior transformer model for pan-allelic peptide–MHC-I presentation prediction, with diverse negative coverage, deconvolution and protein language features. Preprint at bioRxiv https://doi.org/10.1101/2022.12.08.519673 (2022).
Burger, M. L. et al. Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell 184, 4996–5014.e26 (2021).
Google Scholar
Bechter, O. et al. 706 NOUS-PEV, a novel personalized viral-based prime/boost cancer immunotherapy targeting patient-specific neoantigens: interim results from the first subjects in the phase 1b study (Regular and Young Investigator Award Abstract). J. Immunother. Cancer 10, A738 (2022).
D’Alise, A. M. et al. Phase I trial of viral vector based personalized vaccination elicits robust neoantigen specific antitumor T cell responses. Clin. Cancer Res. 30, 2412–2423 (2024).
Google Scholar
Rappaport, A. R. et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 30, 1013–1022 (2024).
Google Scholar
Walter, S. et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18, 1254–1261 (2012).
Google Scholar
Cafri, G. et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J. Clin. Invest. 130, 5976–5988 (2020).
Google Scholar
Yoshitake, Y. et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin. Cancer Res. 21, 312–321 (2015).
Google Scholar
Somaiah, N. et al. A phase 1b study evaluating the safety, tolerability, and immunogenicity of CMB305, a lentiviral-based prime-boost vaccine regimen, in patients with locally advanced, relapsed, or metastatic cancer expressing NY-ESO-1. OncoImmunology 9, 1847846 (2020).
Google Scholar
Sundar, R. et al. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer 18, 332 (2018).
Google Scholar
Ding, Z. et al. Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal. Transduct. Target. Ther. 6, 26 (2021).
Google Scholar
Kaida, M. et al. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J. Immunother. 34, 92–99 (2011).
Google Scholar
Lanitis, E., Dangaj, D., Irving, M. & Coukos, G. Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann. Oncol. 28, xii18–xii32 (2017).
Google Scholar
Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74–80 (2015).
Google Scholar
Rosenbaum, P. et al. Vaccine inoculation route modulates early immunity and consequently antigen-specific immune response. Front. Immunol. 12, 645210 (2021).
Google Scholar
Darrah, P. A. et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature 577, 95–102 (2020).
Google Scholar
Baharom, F. et al. Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment. Cell 185, 4317–4332.e15 (2022).
Google Scholar
Sultan, H. et al. The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. Cancer Immunol. Immunother. 68, 455–466 (2019).
Google Scholar
Lynn, G. M. et al. Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat. Biotechnol. 38, 320–332 (2020).
Google Scholar
Ramirez-Valdez, R. A. et al. Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression. Cell Rep. 42, 112599 (2023).
Google Scholar
Verma, N. K. et al. Obstacles for T-lymphocytes in the tumour microenvironment: therapeutic challenges, advances and opportunities beyond immune checkpoint. eBioMedicine 83, 104216 (2022).
Google Scholar
Neo, S. Y. & Lundqvist, A. The multifaceted roles of CXCL9 within the tumor microenvironment. Adv. Exp. Med. Biol. 1231, 45–51 (2020).
Google Scholar
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405–414 (2015).
Google Scholar
Xue, D. et al. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. Sci. Immunol. 7, eabi6899 (2022).
Google Scholar
Cheng, S. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184, 792–809.e23 (2021).
Google Scholar
Mulder, K. et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity 54, 1883–1900.e5 (2021).
Google Scholar
Zhang, Y. et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 39, 1578–1593.e8 (2021).
Google Scholar
Pittet, M. J., Michielin, O. & Migliorini, D. Clinical relevance of tumour-associated macrophages. Nat. Rev. Clin. Oncol. 19, 402–421 (2022).
Google Scholar
Komohara, Y., Jinushi, M. & Takeya, M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 105, 1–8 (2014).
Google Scholar
Hirano, R. et al. Tissue-resident macrophages are major tumor-associated macrophage resources, contributing to early TNBC development, recurrence, and metastases. Commun. Biol. 6, 144 (2023).
Google Scholar
Dunsmore, G. et al. Timing and location dictate monocyte fate and their transition to tumor-associated macrophages. Sci. Immunol. 9, eadk3981 (2024).
Google Scholar
Zhang, L. et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell 181, 442–459.e29 (2020).
Google Scholar
Sharma, A., Blériot, C., Currenti, J. & Ginhoux, F. Oncofetal reprogramming in tumour development and progression. Nat. Rev. Cancer 22, 593–602 (2022).
Google Scholar
Sharma, A. et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell 183, 377–394.e21 (2020).
Google Scholar
Ramos, R. N. et al. Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. Cell 185, 1189–1207.e25 (2022).
Google Scholar
van Elsas, M. J. et al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell 42, 1032–1050.e10 (2024).
Google Scholar
Kiss, M., Caro, A. A., Raes, G. & Laoui, D. Systemic reprogramming of monocytes in cancer. Front. Oncol. 10, 1399 (2020).
Google Scholar
Ugel, S., Canè, S., Sanctis, F. D. & Bronte, V. Monocytes in the tumor microenvironment. Annu. Rev. Pathol. Mech. Dis. 16, 93–122 (2021).
Google Scholar
Chen, Z., Han, F., Du, Y., Shi, H. & Zhou, W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal. Transduct. Target. Ther. 8, 70 (2023).
Google Scholar
Lin, N. & Simon, M. C. Hypoxia-inducible factors: key regulators of myeloid cells during inflammation. J. Clin. Invest. 126, 3661–3671 (2016).
Google Scholar
Geiger, R. et al. l-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell 167, 829–842.e13 (2016).
Google Scholar
Hanna, R. N. et al. Patrolling monocytes control tumor metastasis to the lung. Science 350, 985–990 (2015).
Google Scholar
Patysheva, M. et al. Monocyte programming by cancer therapy. Front. Immunol. 13, 994319 (2022).
Google Scholar
Marciscano, A. E. & Anandasabapathy, N. The role of dendritic cells in cancer and anti-tumor immunity. Semin. Immunol. 52, 101481 (2021).
Google Scholar
Moussion, C. & Delamarre, L. Antigen cross-presentation by dendritic cells: a critical axis in cancer immunotherapy. Semin. Immunol. 71, 101848 (2024).
Google Scholar
Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7–24 (2020).
Google Scholar
Cabeza-Cabrerizo, M., Cardoso, A., Minutti, C. M., Costa, M. Pda & Reis e Sousa, C.Dendritic cells revisited. Annu. Rev. Immunol. 39, 131–166 (2021).
Google Scholar
Ferris, S. T. et al. cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. Nature 584, 624–629 (2020).
Google Scholar
Kvedaraite, E. & Ginhoux, F. Human dendritic cells in cancer. Sci. Immunol. 7, eabm9409 (2022).
Google Scholar
Lin, J. H. et al. Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. J. Exp. Med. 217, e20190673 (2020).
Google Scholar
Böttcher, J. P. & Sousa, C. R. E. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer 4, 784–792 (2018).
Google Scholar
Meiser, P. et al. A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. Cancer Cell 41, 1498–1515.e10 (2023).
Google Scholar
Duong, E. et al. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Immunity 55, 308–323.e9 (2022).
Google Scholar
Speiser, D. E., Chijioke, O., Schaeuble, K. & Münz, C. CD4+ T cells in cancer. Nat. Cancer 4, 317–329 (2023).
Google Scholar
Michea, P. et al. Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. Nat. Immunol. 19, 885–897 (2018).
Google Scholar
Zhou, B., Lawrence, T. & Liang, Y. The role of plasmacytoid dendritic cells in cancers. Front. Immunol. 12, 749190 (2021).
Google Scholar
Maier, B. et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 580, 257–262 (2020).
Google Scholar
Zilionis, R. et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity 50, 1317–1334.e10 (2019).
Google Scholar
Zhang, Q. et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell 179, 829–845.e20 (2019).
Google Scholar
LaMarche, N. M. et al. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature 625, 166–174 (2023).
Google Scholar
Li, J. et al. Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): a novel population in the tumour microenvironment and immunotherapy target. Clin. Transl. Med. 13, e1199 (2023).
Google Scholar
Oh, S. A. et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat. Cancer 1, 681–691 (2020).
Google Scholar
Leader, A. M. et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell 39, 1594–1609.e12 (2021).
Google Scholar
Xie, Y.-J. et al. Overcoming suppressive tumor microenvironment by vaccines in solid tumor. Vaccines 11, 394 (2023).
Google Scholar
Kwart, D. et al. Cancer cell-derived type I interferons instruct tumor monocyte polarization. Cell Rep. 41, 111769 (2022).
Google Scholar
Beck, J. D. et al. Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers. Cancer Cell 42, 568–582.e11 (2024).
Google Scholar
Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401 (2016).
Google Scholar
Salomon, N. et al. Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer. Cancer Immunol. Immunother. 71, 1975–1988 (2022).
Google Scholar
Zhang, Z., Liu, X., Chen, D. & Yu, J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal. Transduct. Target. Ther. 7, 258 (2022).
Google Scholar
Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).
Google Scholar
Hecht, J. R. et al. Abstract CT007: safety and immunogenicity of a personalized neoantigen–Listeria vaccine in cancer patients (abstract). Cancer Res. 79, CT007 (2019).
Google Scholar
Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632–644 (2024).
Google Scholar
Di, J. et al. Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size. Pharm. Res. 39, 105–114 (2022).
Google Scholar
Hotz, C. et al. Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci. Transl. Med. 13, eabc7804 (2021).
Google Scholar
Ablasser, A. & Chen, Z. J. cGAS in action: expanding roles in immunity and inflammation. Science 363, eaat8657 (2019).
Google Scholar
Samson, N. & Ablasser, A. The cGAS–STING pathway and cancer. Nat. Cancer 3, 1452–1463 (2022).
Google Scholar
Lellahi, S. M. et al. GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2. Front. Immunol. 13, 1058963 (2023).
Google Scholar
Mooney, C. J., Cunningham, A., Tsapogas, P., Toellner, K.-M. & Brown, G. Selective expression of Flt3 within the mouse hematopoietic stem cell compartment. Int. J. Mol. Sci. 18, 1037 (2017).
Google Scholar
Tang, T. et al. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal. Transduct. Target. Ther. 6, 72 (2021).
Google Scholar
Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989–2003 (2011).
Google Scholar
Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 23, 543–555 (2022).
Google Scholar
Liao, J. et al. Type I IFNs repolarized a CD169+ macrophage population with anti-tumor potentials in hepatocellular carcinoma. Mol. Ther. 30, 632–643 (2022).
Google Scholar
Gajewski, T. F., Louahed, J. & Brichard, V. G. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 16, 399–403 (2010).
Google Scholar
Zeestraten, E. C. M. et al. Addition of interferon‐α to the p53‐SLP® vaccine results in increased production of interferon‐γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int. J. Cancer 132, 1581–1591 (2013).
Google Scholar
Cao, X. et al. Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nat. Commun. 12, 5866 (2021).
Google Scholar
Palma, M. D. et al. Tumor-targeted interferon-α delivery by tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14, 299–311 (2008).
Google Scholar
Pogue, S. L. et al. Targeting attenuated interferon-α to myeloma cells with a CD38 antibody induces potent tumor regression with reduced off-target activity. PLoS ONE 11, e0162472 (2016).
Google Scholar
Rolfo, C., Giovannetti, E., Martinez, P., McCue, S. & Naing, A. Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer. NPJ Precis. Oncol. 7, 26 (2023).
Google Scholar
Kyi, C. et al. Therapeutic immune modulation against solid cancers with intratumoral poly-ICLC: a pilot trial. Clin. Cancer Res. 24, 4937–4948 (2018).
Google Scholar
Hammerich, L. et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat. Med. 25, 814–824 (2019).
Google Scholar
Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515–525 (2021).
Google Scholar
Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234–239 (2019).
Google Scholar
Everson, R. G. et al. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II trial. Nat. Commun. 15, 3882 (2024).
Google Scholar
Williams, B. B., Paul, R. T. & Lerner, A. M. Pharmacokinetics of interferon in blood, cerebrospinal fluid, and brain after administration of modified polyriboinosinic-polyribocytidylic acid and amphotericin B. J. Infect. Dis. 146, 819–825 (1982).
Google Scholar
Ye, J. et al. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer. J. Immunother. Cancer 10, e004784 (2022).
Google Scholar
Mullins, S. R. et al. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies. J. Immunother. Cancer 7, 244 (2019).
Google Scholar
Yoo, Y. J. et al. Nanoengineered macrophages armed with TLR7/8 agonist enhance remodeling of immunosuppressive tumor microenvironment. Small 20, e2307694 (2024).
Google Scholar
Woo, S.-R., Corrales, L. & Gajewski, T. F. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 36, 250–256 (2015).
Google Scholar
Corrales, L. et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11, 1018–1030 (2015).
Google Scholar
Sivick, K. E. et al. Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity. Cell Rep. 25, 3074–3085.e5 (2018).
Google Scholar
Fu, J. et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl. Med. 7, 283ra52 (2015).
Google Scholar
He, Y. et al. STING protein‐based in situ vaccine synergizes CD4+ T, CD8+ T, and NK cells for tumor eradication. Adv. Healthc. Mater. 12, e2300688 (2023).
Google Scholar
Meric-Bernstam, F. et al. Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib study. Clin. Cancer Res. 29, 110–121 (2022).
Google Scholar
Larkin, B. et al. Cutting edge: activation of STING in T cells induces type I IFN responses and cell death. J. Immunol. 199, 397–402 (2017).
Google Scholar
Cerboni, S. et al. Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes. J. Exp. Med. 214, 1769–1785 (2017).
Google Scholar
Zhu, Y. et al. STING: a master regulator in the cancer-immunity cycle. Mol. Cancer 18, 152 (2019).
Google Scholar
Smith, K. E., Deronic, A., Hägerbrand, K., Norlén, P. & Ellmark, P. Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. Expert. Opin. Biol. Ther. 21, 1635–1646 (2021).
Google Scholar
Morrison, A. H., Diamond, M. S., Hay, C. A., Byrne, K. T. & Vonderheide, R. H. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. Proc. Natl Acad. Sci. USA 117, 8022–8031 (2020).
Google Scholar
Wattenberg, M. M. et al. Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1. Sci. Immunol. 8, eadj5097 (2023).
Google Scholar
Salomon, R. & Dahan, R. Next generation CD40 agonistic antibodies for cancer immunotherapy. Front. Immunol. 13, 940674 (2022).
Google Scholar
Soto, M. et al. Neoadjuvant CD40 agonism remodels the tumor immune microenvironment in locally advanced esophageal/gastroesophageal junction cancer. Cancer Res. Commun. 4, 200–212 (2024).
Google Scholar
Anandasabapathy, N. et al. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transpl. 50, 924–930 (2015).
Google Scholar
Maraskovsky, E. et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184, 1953–1962 (1996).
Google Scholar
Sánchez-Paulete, A. R. et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti–PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 6, 71–79 (2016).
Google Scholar
Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638–652 (2014).
Google Scholar
Bhardwaj, N. et al. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nat. Cancer 1, 1204–1217 (2020).
Google Scholar
Cannarile, M. A. et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer 5, 53 (2017).
Google Scholar
Cassetta, L. & Pollard, J. W. Targeting macrophages: therapeutic approaches in cancer. Nat. Rev. Drug Discov. 17, 887–904 (2018).
Google Scholar
Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21, 799–820 (2022).
Google Scholar
Timperi, E. et al. Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer. Cancer Res. 82, 3291–3306 (2022).
Google Scholar
Wolf, E. M., Fingleton, B. & Hasty, A. H. The therapeutic potential of TREM2 in cancer. Front. Oncol. 12, 984193 (2022).
Google Scholar
Katzenelenbogen, Y. et al. Coupled scRNA-seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell 182, 872–885.e19 (2020).
Google Scholar
Binnewies, M. et al. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep. 37, 109844 (2021).
Google Scholar
Molgora, M. et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell 182, 886–900.e17 (2020).
Google Scholar
Park, M. D. et al. TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. Nat. Immunol. 24, 792–801 (2023).
Google Scholar
Patnaik, A. et al. A phase 1a dose-escalation study of PY314, a TREM2 (triggering receptor expressed on macrophages 2) targeting monoclonal antibody (abstract). J. Clin. Oncol. 40, 2648 (2022).
Google Scholar
Chan, M. K.-K. et al. Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy. Explor. Target. Anti-tumor Ther. 4, 316–343 (2023).
Google Scholar
Wischhusen, J., Melero, I. & Fridman, W. H. Growth/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Front. Immunol. 11, 951 (2020).
Google Scholar
Huynh, L. K., Hipolito, C. J. & Dijke, Pten A perspective on the development of TGF-β inhibitors for cancer treatment. Biomolecules 9, 743 (2019).
Google Scholar
Kim, B.-G., Malek, E., Choi, S. H., Ignatz-Hoover, J. J. & Driscoll, J. J. Novel therapies emerging in oncology to target the TGF-β pathway. J. Hematol. Oncol. 14, 55 (2021).
Google Scholar
Ratnam, N. M. et al. NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development. J. Clin. Invest. 127, 3796–3809 (2017).
Google Scholar
Urakawa, N. et al. GDF15 derived from both tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression via Akt and Erk pathways. Lab. Invest. 95, 491–503 (2015).
Google Scholar
Hong, G. et al. Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 149, 159–171 (2023).
Google Scholar
Haake, M. et al. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment. Nat. Commun. 14, 4253 (2023).
Google Scholar
Bermejo, I. M. et al. Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL). J. Clin. Oncol. 41, 2501 (2023).
Google Scholar
Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782–795 (2013).
Google Scholar
Thorsson, V. et al. The immune landscape of cancer. Immunity 51, 411–412 (2019).
Google Scholar
Fitzgerald, B. G. et al. Abstract CT205: a phase I/Ib trial of intratumoral Poly-ICLC in resectable malignant pleural mesothelioma (abstract). Cancer Res. 82, CT205 (2022).
Google Scholar
Klebanoff, C. A., Acquavella, N., Yu, Z. & Restifo, N. P. Therapeutic cancer vaccines: are we there yet? Immunol. Rev. 239, 27–44 (2011).
Google Scholar
Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909–915 (2004).
Google Scholar
Lynn, G. M. et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat. Biotechnol. 33, 1201–1210 (2015).
Google Scholar
Zelba, H. et al. Adjuvant treatment for breast cancer patients using individualized neoantigen peptide vaccination—a retrospective observation. Vaccines 10, 1882 (2022).
Google Scholar
Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med. 30, 531–542 (2024).
Google Scholar
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mater. 16, 489–496 (2017).
Google Scholar
Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M. & Marques, M. P. C. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine 39, 2190–2200 (2021).
Google Scholar
Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532–542 (2022).
Google Scholar
Gebre, M. S. et al. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature 601, 410–414 (2022).
Google Scholar
Morais, P., Adachi, H. & Yu, Y.-T. The critical contribution of pseudouridine to mRNA COVID-19 vaccines. Front. Cell Dev. Biol. 9, 789427 (2021).
Google Scholar
Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248–251 (2017).
Google Scholar
Comes, J. D. G., Pijlman, G. P. & Hick, T. A. H. Rise of the RNA machines—self-amplification in mRNA vaccine design. Trends Biotechnol. 41, 1417–1429 (2023).
Google Scholar
Amaya, L. et al. Circular RNA vaccine induces potent T cell responses. Proc. Natl Acad. Sci. USA 120, e2302191120 (2023).
Google Scholar
Naka, T. et al. Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony‐stimulating factor RNA. Cancer Sci. 99, 407–413 (2008).
Google Scholar
Minkis, K. et al. Type 2 bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res. 68, 9441–9450 (2008).
Google Scholar
Bergh, J. Vden et al. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget 6, 44123–44133 (2015).
Google Scholar
Yang, J. et al. Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy. Mol. Ther. Nucleic Acids 30, 184–197 (2022).
Google Scholar
Chen, S. et al. Nanotechnology-based mRNA vaccines. Nat. Rev. Methods Prim. 3, 63 (2023).
Google Scholar
Kiaie, S. H. et al. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J. Nanobiotechnol. 20, 276 (2022).
Google Scholar
Alameh, M.-G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892.e7 (2021).
Google Scholar
Coughlan, L. Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines. Front. Immunol. 11, 909 (2020).
Google Scholar
Atmar, R. L. et al. Homologous and heterologous COVID-19 booster vaccinations. N. Engl. J. Med. 386, 1046–1057 (2022).
Google Scholar
Fausther-Bovendo, H. & Kobinger, G. P. Pre-existing immunity against Ad vectors. Hum. Vaccines Immunother. 10, 2875–2884 (2014).
Google Scholar
Reyes-Sandoval, A. et al. Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Mol. Ther. 20, 1633–1647 (2012).
Google Scholar
Harper, D. M. & DeMars, L. R. HPV vaccines—a review of the first decade. Gynecol. Oncol. 146, 196–204 (2017).
Google Scholar
Banister, C. E., Liu, C., Pirisi, L., Creek, K. E. & Buckhaults, P. J. Identification and characterization of HPV-independent cervical cancers. Oncotarget 8, 13375–13386 (2017).
Google Scholar
Tran, E., Urba, W. J. & Leidner, R. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med. 387, 573–574 (2022).
Google Scholar
Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641–645 (2014).
Google Scholar
Paston, S. J., Brentville, V. A., Symonds, P. & Durrant, L. G. Cancer vaccines, adjuvants, and delivery systems. Front. Immunol. 12, 627932 (2021).
Google Scholar
Diefenbach, C. S. M. et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin. Cancer Res. 14, 2740–2748 (2008).
Google Scholar
Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).
Google Scholar
Sabado, R. L. et al. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer Immunol. 3, 278–287 (2015).
Google Scholar
Karbach, J. et al. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naïve prostate cancer patients. Clin. Cancer Res. 17, 861–870 (2011).
Google Scholar
Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144–150 (2023).
Google Scholar
Liang, F. et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol. Ther. 25, 2635–2647 (2017).
Google Scholar
Ewer, K. J. et al. Viral vectors as vaccine platforms: from immunogenicity to impact. Curr. Opin. Immunol. 41, 47–54 (2016).
Google Scholar
Balachandran, V. P. et al. Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma (abstract). J. Clin. Oncol. 40, 2516 (2022).
Google Scholar
Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619–1629 (2022).
Google Scholar
Lopez, J. et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat. Med. (in the press).
